Pharmacy Grand Rounds
Emicizumab: A Safe HAVEN in Hemophilia A

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

First FDA-approved in 2017, emicizumab heralds a new paradigm in the management of hemophilia A. Unlike intravenous factor VIII preparations, emicizumab is a subcutaneous, bispecific monoclonal antibody with activity in patients with and without inhibitors to factor VIII. During this session, participants will examine the results of the landmark HAVEN trial series and evaluate real-world practice implications of this therapy.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Describe the mechanism of action of emicizumab
2. Outline significant findings from the HAVEN 1-4 trials
3. Identify practical considerations regarding the use of emicizumab in persons with hemophilia A

Session Announcement

Session Slides

FACULTY INFORMATION

Alexis K. Kuhn, PharmD, BCOP
Pediatric Oncology Pharmacist - Ambulatory Services
Mayo Clinic Hospital - Rochester, MN

Alexis is the pediatric hematology/oncology ambulatory pharmacist at Mayo Clinic in Rochester. She received a Doctor of Pharmacy degree from the University of Utah, after which she completed a PGY1 residency at Mayo Eugenio Litta Children’s Hospital followed by a PGY2 in oncology pharmacy at Mayo Clinic Hospital – Rochester. She is passionate about caring for pediatric patients with malignancies and benign hematologic conditions.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Alexis K. Kuhn, PharmD, BCOP
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will not be discussed during this presentation.

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS